natgillin/translations-raw huggingface dataset:
Epoetin beta, the active substance of NeoRecormon is identical in its amino acid and carbohydrate composition to erythropoietin that has been isolated from the urine of anaemic patients.
Epoetin beta, djelatna tvar lijeka NeoRecormon, je, po svom sadržaju aminokiselina i ugljikohidrata, identičan eritropoetinu izoliranom iz urina anemičnih bolesnika.
Epoetin beta, the active substance of NeoRecormon, is identical in its amino acid and carbohydrate composition to erythropoietin that has been isolated from the urine of anaemic patients.
Epoetin beta, djelatna tvar lijeka NeoRecormon, je, po svom sadržaju aminokiselina i ugljikohidrata, identičan eritropoetinu izoliranom iz urina anemičnih bolesnika.
Epoetin beta, the active substance of NeoRecormon, is identical in its amino acid and carbohydrate composition to erythropoietin that has been isolated from the urine of anaemic patients.
Epoetin beta, djelatna tvar NeoRecormona, je, po svom sadržaju aminokiselina i ugljikohidrata, identičan eritropoetinu izoliranom iz urina anemičnih bolesnika.
Epoetin theta (recombinant human erythropoietin) is produced in Chinese Hamster Ovary Cells (CHO-K1) by recombinant DNA technology.
Epoetin theta (rekombinantni humani eritropoetin) proizveden je tehnologijom rekombinantne DNK na stanicama ovarija kineskog hrčka (CHO-K1).
Epoetin theta should be administered either subcutaneously or intravenously in order to increase haemoglobin level to not greater than 12 g/dl (7.45 mmol/l).
Epoetin theta treba primjenjivati bilo supkutano ili intravenski kako bi se vrijednost hemoglobina povećala na najviše 12 g/dl (7,45 mmol/l).
Epoetin theta treatment should be initiated by physicians experienced in the above-mentioned indications.
Liječenje epoetinom theta trebaju započeti liječnici s iskustvom u navedenim indikacijama.
Epoetin zeta is identical in its amino acid sequence and similar in carbohydrate composition to endogenous human erythropoietin that has been isolated from the urine of anaemic patients.
Epoetin zeta ima identičan redoslijed aminokiselina i sličan sastav ugljikohidrata kao i endogeni ljudski eritropoetin izoliran iz urina anemičnih bolesnika.
Epoprostenol: limited data obtained from a study (AC-052-356 [BREATHE-3]) in which 10 paediatric patients received the combination of bosentan and epoprostenol indicate that after both single- and multiple-dose administration, the Cmax and AUC values of bosentan were similar in patients with or without continuous infusion of epoprostenol (see section 5.1).
Epoprostenol: ograničeni podaci dobiveni iz studije (AC-052-356 [BREATHE-3]) u kojoj je 10 pedijatrijskih bolesnika dobilo kombinaciju bosentana i epoprostenola pokazuju da su i nakon primjene jednokratnih i višekratnih doza vrijednosti Cmax i AUC bosentana bile slične u bolesnika sa ili bez kontinuirane infuzije epoprostenola (vidjeti dio 5.1).
Eporatio
EU/1/09/573/003
Eporatio
EU/1/09/573/004
Eporatio
EU/1/09/573/005
Eporatio
EU/1/09/573/006
Eporatio
EU/1/09/573/007
Eporatio
EU/1/09/573/008
Eporatio
EU/1/09/573/009
Eporatio
EU/1/09/573/010
Eporatio
EU/1/09/573/011
Eporatio
EU/1/09/573/012
Eporatio
EU/1/09/573/013
Eporatio
EU/1/09/573/014
Eporatio
EU/1/09/573/015
Eporatio
EU/1/09/573/016
Eporatio
EU/1/09/573/017
Eporatio
EU/1/09/573/018
Eporatio
EU/1/09/573/019
Eporatio
EU/1/09/573/020
Eporatio
EU/1/09/573/021
Eporatio
EU/1/09/573/022
Eporatio
EU/1/09/573/024
Eporatio
EU/1/09/573/025
Eporatio
EU/1/09/573/026
Eporatio
EU/1/09/573/027
Eporatio
EU/1/09/573/028
Eporatio
EU/1/09/573/030
Eporatio
EU/1/09/573/031
Eporatio
EU/1/09/573/032
Eporatio
EU/1/09/573/033
Eporatio
EU/1/09/573/034
Eporatio
EU/1/09/573/035
Eporatio
EU/1/09/573/036
Eporatio
EU/1/09/573/037
Eporatio
EU/1/09/573/038
Eporatio
EU/1/09/573/039
Eporatio
EU/1/09/573/040
Eporatio
EU/1/09/573/041
Eporatio
EU/1/09/573/042
Eporatio 1,000 IU/0.5 ml
Eporatio 1000 IU/0,5 ml
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Eporatio 2,000 IU/0.5 ml
Eporatio 2000 IU/0,5 ml
Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 2000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/09/573/003
Eporatio 2000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/003
Eporatio 3,000 IU/0.5 ml
Eporatio 3000 IU/0,5 ml
Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 3000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Eporatio 4,000 IU/0.5 ml
Eporatio 4000 IU/0,5 ml
Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 4000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Eporatio 5,000 IU/0.5 ml
Eporatio 5000 IU/0,5 ml
Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Eporatio is used for the treatment of anaemia accompanied by symptoms (for example fatigue, weakness and shortness of breath).
Eporatio se koristi u liječenju slabokrvnosti (anemije) praćene simptomima (na primjer, umorom, slabošću ili nedostatkom zraka).
EPP patients with fair skin may be more likely to request treatment and are more prone to developing UV light-associated skin changes, including cancer;
Izglednije je da će bolesnici s EPP-om blijede puti zatražiti liječenje i da će biti skloniji razvijanju promjena kože povezanih s UV svjetlom, uključujući i rak;
Eprinomectin (mg)
Eprinomektin (mg)
Eprinomectin 1.20 mg
Eprinomektin 1,20 mg
Eprinomectin 3.60 mg
Eprinomektin 3,60 mg
Eprinomectin and praziquantel act systemically, with plasma concentrations reaching a maximum within 48 hours and 6 hours after treatment, respectively, reaching mean maximum concentrations (Cmax) of 20.1 ng/ml for eprinomectin and 157 ng/ml for praziquantel.
Eprinomektin i prazikvantel djeluju sustavno uz maksimalnu koncentraciju u roku od 48 sati i 6 sati nakon tretmana, odnosno postizanja maksimalne koncentracije (Cmax) od 20,1 ng/ml za eprinomektin i 157 ng/ml za prazikvantel.
Eprinomectin interferes with channels in the nerve and muscle cells of roundworms that allow charged chloride particles (ions) to pass, leading to their paralysis and death.
Eprinomektin interferira s kanalima u živcima i mišićima oblića koji omogućuju prolazak nabijenih kloridnih čestica (iona), uzrokujući njihovu paralizu i smrt.
Eprinomectin is a member of the macrocyclic lactone class of endectocides.
Eprinomektin je makrociklički lakton iz skupine endektocida.
epsis (serious infection which can result in organ failure, shock or death)
epsa (teška infekcija koja uzrokuje zatajivanje organa, šok ili smrt)
epsis*
epsa
epsis* (including bacterial, viral and fungal), neutropenic sepsis*, respiratory tract infection (includes upper and bronchitis), urinary tract infection, cellulitis, diverticulitis, oral fungal infection, sinusitis, pharyngitis, rhinitis, herpes simplex, skin infection
epsa* (uključujući bakterijsku, virusnu i gljivičnu), neutropenična sepsa*, infekcija dišnih puteva (uključuje gornje dišne puteve i bronhitis), infekcija mokraćnih puteva, celulitis, divertikulitis, oralna gljivična infekcija, sinusitis, faringitis, rinitis, herpes simplex, kožna infekcija
epsis, septic shock, infection of the meninges (meningococcal meningitis), infection of the lung (pneumonia), stomach flu (gastrointestinal infection), cystitis,, lower respiratory tract infection
epsa, septički šok, infekcija moždanih ovojnica (meningokokni meningitis), infekcija pluća (pneumonija), želučana gripa (gastrointestinalna infekcija), upala mokraćnog mjehura (cistitis), upala donjih dišnih puteva
Epstein-Barr Virus-associated lymphoproliferative disorders
Limfoproliferacijski poremećaji povezani s Epstein-Barrovim virusom
Epstein-Barr Virus-associated lymphoproliferative disorders have been observed outside company-sponsored studies.
Izvan opsega ispitivanja koje je sponzorirala kompanija primijećeni su limfoproliferacijski poremećaji povezani s Epstein-Barrovim virusom.
eptacog alfa (activated)
eptakog alfa (aktivirani)
Eptacog alfa is not extracted from human blood but is produced by a method known as ‘recombinant DNA technology’: it is made by cells that have received a gene (DNA), which makes them able to produce eptacog alfa.
Eptakog alfa ne ekstrahira se iz ljudske krvi, nego se proizvodi metodom poznatom kao „tehnologija rekombinantne DNK”: ovu tvar proizvode stanice koje su primile gen (DNK) koji im omogućuje da stvaraju eptakog alfa.
eptic inflammation of a vein with blood clotting (septic thrombophlebitis) or blocked blood vessels at an infected site
eptička upala vene sa zgrušavanjem krvi (septički tromboflebitis) ili začepljene krvne žile na mjestu infekcije
eptic shock*
eptički šok
eptic thrombophlebitis or occluded arteriovenous cannula at seriously infected site
eptički tromboflebitis ili začepljena arteriovenska kanila na ozbiljno inficiranom mjestu
Eptifibatide
Eptifibatid
Eptifibatide Accord 2 mg/ml solution for injection eptifibatide
Eptifibatid Accord 2 mg/m lotopina za injekciju eptifibatid
Eptifibatide Accord infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy or if the patient must undergo an emergency CABG surgery or requires an intraortic balloon pump.
Infuziju Eptifibatid Accord A treba odmah prekinuti ako nastupe okolnosti koje zahtijevaju primjenu trombolitičke terapije ili ako bolesnik mora pristupiti hitnoj ugradnji premosnice koronarne arterije (CABG) ili zahtijeva intraaortnu balon pumpu.
Eptifibatide Accord infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy or if the patient must undergo an emergency CABG surgery or requires an intraortic balloon pump.
Infuziju Eptifibatid Accorda treba odmah prekinuti ako nastupe okolnosti koje zahtijevaju primjenu trombolitičke terapije ili ako bolesnik mora pristupiti hitnoj ugradnji premosnice koronarne arterije (CABG) ili zahtijeva intraaortnu balon pumpu.
Eptifibatide Accord is a ‘generic medicine’.
Eptifibatide Accord je „generički lijek”.
Eptifibatide Accord is also intended for concurrent use with acetylsalicylic acid, as it is part of standard management of patients with acute coronary syndromes, unless its use is contraindicated.
Eptifibatid Accord je također namijenjen za istodobnu primjenu s acetilsalicilatnom kiselinom (ASK), budući da je dio standardnog načina zbrinjavanja bolesnika s akutnim koronarnim sindromima, ukoliko njegova primjena nije kontraindicirana.
Eptifibatide Accord is an antithrombotic agent that acts by inhibition of platelet aggregation; therefore the patient must be observed carefully for indications of bleeding during treatment (see section 4.8).
Eptifibatid Accord je antitrombotik koji djeluje inhibicijom agregacije trombocita, stoga bolesnika treba pomno nadzirati zbog naznaka krvarenja tijekom liječenja (vidjeti dio 4.8.).
Eptifibatide Accord is chemically and physically compatible with 0.9 % sodium chloride solution for infusion and with dextrose 5 % in Normosol R with or without potassium chloride up to 92 hours when stored at 20-25°C. Please refer to the Normosol R Summary of Product Characteristics for details on its composition.
Eptifibatid Accord je kemijski i fizikalno kompatibilan s 0,9 %- tnom otopinom natrijevog klorida za infuziju i 5 %- tnom glukozom u Normosolu R s ili bez kalijevog klorida do 92 sata kada se čuva na temperaturi od 20-25 °C. Molimo pogledati Sažetak opisa svojstava lijeka Normosol R otopine za detaljni sastav iste.
Eptifibatide Accord is chemically and physically compatible with 0.9 % sodium chloride solution for infusion and with dextrose 5 % in Normosol R with or without potassium chloride up to 92 hours when stored at 20-25°C. Please refer to the Normosol R Summary of Product Characteristics for details on its composition.
Eptifibatid Accord je kemijski i fizikalno kompatibilan s 0,9 %- tnom otopinom natrijevog klorida za infuziju i 5 %- tnom glukozom u Normosolu R, s ili bez kalijevog klorida do 92 sata kada se čuva na temperaturi od 20-25 °C. Molimo pogledati Sažetak opisa svojstava lijeka Normosol R otopine za detaljni sastav iste.
Eptifibatide Accord is not intended for use in children or adolescents less than 18 years of age.
Eptifibatid Accord nije namijenjen za primjenu u djece ili adolescenata mlađih od 18 godina.
Eptifibatide Accord is recommended for use only in adult, hospitalised patients in coronary care units.
Eptifibatid Accord se preporučuje za primjenu jedino u odraslih bolesnika, koji se nalaze u bolnici u koronarnim jedinicama.
Eptifibatide Accord is recommended for use only in adult, hospitalised patients in coronary care units.
Eptifibatid Accord se preporučuje za primjenu jedino u odraslih bolesnika, koji se nalaze u koronarnim jedinicama.
Eptifibatide Accord must not be used to treat patients with:
Eptifibatid Accord ne smiju koristiti bolesnici:
Eptifibatide inhibits platelet aggregation in a dose- and concentration-dependent manner as demonstrated by ex vivo platelet aggregation using adenosine diphosphate (ADP) and other agonists to induce platelet aggregation.
Eptifibatid inhibira agregaciju trombocita ovisno o dozi i koncentraciji što je pokazano ex vivo agregacijom trombocita pomoću adenozin-difosfata (ADP) i drugih agonista koji induciraju agregaciju trombocita.
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein (GP) IIb/IIIa receptors.
Eptifibatid reverzibilno inhibira agregaciju trombocita sprječavajući vezivanje fibrogena, von Willebrandovog faktora i drugih adhezivnih liganada za receptore glikoproteina (GP) IIb/IIIa.
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein (GP)IIb/IIIa receptors.
Eptifibatid reverzibilno inhibira agregaciju trombocita sprječavajući vezivanje fibrogena, von Willebrandovog faktora i drugih adhezivnih liganada za receptore glikoproteina (GP) IIb/IIIa.
eptifibatide,
eptifibatid
eptifibatide,
eptifibatid,
Eptotermin alfa in Freund’s adjuvant was first administered subcutaneously with booster doses given after 14 and 28 days.
Eptotermin alfa u Freundovom adjuvansu prvo je primijenjen supkutano, a dodatne doze primijenjene su nakon 14 i 28 dana.
eptum pellucidum agenesis; olfactory nerve agenesis.
ageneze septuma pellucidum ageneze olfaktornog živca.
Epworth Sleepiness Scale (ESS; range 0-24)
Epworthova skala pospanosti (ESS; raspon 0-24)
Equal amounts of prednisolone, prednisone, 20β- dihydroprednisolone and 20β-dihydroprednisone are found in urine.
Podjednake količine prednizolona, prednisona, 20β- dihidroprednizolona i 20β-dihidroprednisona pronađene su u urinu.
Equilibrate the refrigerated vial of Noxafil to room temperature.
Pustite da se rashlađena bočica lijeka Noxafil ugrije na sobnu temperaturu.
Equilibrate the vial to room temperature (at or below 25°C).
Pričekajte da se bočica ugrije na sobnu temperaturu (25°C ili manje).
Equilis Prequenza Te [a clear pictogram of a horse]
Equilis Prequenza Te [jasan piktogram konja]
Equilis Prequenza Te suspension for injection for horses
Equilis Prequenza Te, suspenzija za injekciju, za konje
Equilis Prequenza Te suspension for injection for horses
Equilis Prequenza Tesuspenzija za injekciju za konje
Equilis StrepE – solvent
Equilis StrepE - otapalo
Equilis StrepE, lyophilisate and solvent for suspension for injection
Equilis StrepE liofilizat i otapalo za suspenziju za injekciju
Equilis StrepE, lyophilisate and solvent for suspension for injection, for horses
Equilis StrepE liofilizat i otapalo za suspenziju za injekciju, za konje
Equilis StrepE, lyophilisate and solvent for suspension for injection, for horses
Equilis StrepE liofilizat za suspenziju za injekciju, za konje
Equilis StrepE, lyophilisate for suspension for injection, for horses
Equilis StrepE liofilizat za suspenziju za injekciju za konje
Equilis Te Equilis Te Equilis Te Equilis Te
EquilisTe EquilisTe EquilisTe EquilisTe
Equilis Te suspension for injection for horses
Equilis Te suspenzija za injekciju za konje
Equilis Te suspension for injection for horses
Equilis Te, suspenzija za injekciju, za konje
Equilis West Nile [a clear pictogram of a horse]
Equilis West Nile
Equilis West Nile suspension for injection
Equilis West Nile suspenzija za injekciju
Equilis West Nile Suspension for injection for horses
Equilis West Nile Suspenzija za injekciju za konje
Equine influenza virus strains:
Sojevi virusa influence konja:
Equip WNV emulsion for injection for horses
Equip WNV emulzija za injekciju za konje
Equip WNV injection for horses
Equip WNV emulzija za injekciju za konje
Equipment for manual ventilation should be available in case of respiratory depression or apnoea when dexmedetomidine and ketamine are used sequentially to induce anaesthesia in cats.
Kad se deksmedetomidin i ketamin koriste sekvencijalno za uvođenje mačaka u anesteziju oprema, za manualnu ventilaciju treba biti dostupna za slučaj depresije disanja ili apneje.
Equipment for manual ventilation should be available in case of respiratory depression or apnoea when dexmedetomidine and ketamine are used sequentially to induce anaesthesia in cats.
Kad se deksmedetomidin i ketamin koriste sekvencijalno za uvođenje mačaka u anesteziju, oprema za manualnu ventilaciju treba biti dostupna za slučaj depresije disanja ili apneje.
Equipment such as vials, needles and syringes used for Pixuvri administration should be handled as toxic waste.
S opremom, kao što su bočice, igle i štrcaljke korištene za primjenu Pixuvria, treba postupati kao s toksičnim otpadom.
Equipment that you need
Potre bni pribor
Equisolon 33 mg/g oral powder for horses Prednisolone
Equisolon 33 mg/g peroralni prašak za konje Prednizolon
Equivalence boundary 70%-143%
Granica ekvivalencije 70%-143
Equivalent to valnemulin base
što odgovara bazi valnemulina
Equivocal
Nepouzdan rezultat
Eravac contains an adjuvant (mineral oil) to enhance the immune response.
Eravac sadrži adjuvans (mineralno ulje) kako bi se pojačala imunosna reakcija.
Eravac contains inactivated rabbit haemorrhagic disease type 2 virus, strain (V-1037), as the active substance.
Eravac sadrži inaktivirani virus hemoragične bolesti kunića tipa 2, soj (V-1037), kao djelatnu tvar.
Eravac contains rabbit haemorrhagic disease type 2 virus (RHDV2),
Eravac sadrži virus hemoragične bolesti kunića tipa 2 (RHDV2), soj V-1037, koji je inaktiviran
ERAVAC emulsion for injection for rabbits
ERAVAC, emulzija za injekciju, za kuniće
ERAVAC emulsion for injection for rabbits
ERAVAC, emulzija za injekciju, za kuniće.
Eravac is a veterinary vaccine used in rabbits intended for meat production to reduce death due to the rabbit haemorrhagic disease (RHD), a usually fatal disease caused by a new variant of RHD virus, called RHD type 2 virus, resulting in blood clot formation.
Eravac je veterinarsko cjepivo koje se daje kunićima namijenjenima za proizvodnju mesa radi smanjenja smrtnosti zbog hemoragične bolesti kunića (RHD), uglavnom smrtonosne bolesti koju uzrokuje novi soj virusa RHDV koji se naziva RHDV tipa 2, a koji uzrokuje stvaranje krvnih ugrušaka.
Eravac is an emulsion containing mineral oil.
Eravac je emulzija koja sadrži mineralno ulje.
Eravac is available as an emulsion for injection and can only be obtained with a prescription.
Eravac je dostupan kao emulzija za injekciju i izdaje se samo na recept.
Eravac rabbit haemorrhagic disease vaccine, inactivated
Eravac cjepivo protiv hemoragične bolesti kunića, inaktivirano
Erbitux 5 mg/mL is compatible with polyethylene (PE), ethyl vinyl acetate (EVA) or polyvinyl chloride (PVC) bags, with polyethylene (PE), polyurethane (PUR), ethyl vinyl acetate (EVA), polyolefine thermoplastic (TP) or polyvinyl chloride (PVC) infusion sets, with polypropylene (PP) syringes for syringe pump.
Erbitux 5 mg/ml je kompatibilan s vrećicama od polietilena (PE), etilvinilacetata (EVA) ili polivinilklorida (PVC), infuzijskim sustavima od polietilena (PE), poliuretana (PUR), etilvinilacetata (EVA), termoplastičnog poliolefina (TP) ili polivinilklorida (PVC), polipropilenskim (PP) štrcaljkama za injekcijsku pumpu
Erbitux 5 mg/mL is compatible with polyethylene (PE), ethyl vinyl acetate (EVA) or polyvinyl chloride (PVC) bags, with polyethylene (PE), polyurethane (PUR), ethyl vinyl acetate (EVA), polyolefine thermoplastic (TP) or polyvinyl chloride (PVC) infusion sets, with polypropylene (PP) syringes for syringe pump.
Erbitux 5 mg/ml je kompatibilan s vrećicama od polietilena (PE), etilvinilacetata (EVA) ili polivinilklorida (PVC), infuzijskim sustavima od polietilena (PE), poliuretana (PUR), etilvinilacetata (EVA), termoplastičnog poliolefina (TP) ili polivinilklorida (PVC), polipropilenskim (PP) štrcaljkama za injekcijsku pumpu.
Erbitux 5 mg/mL solution for infusion
Erbitux 5 mg/ml otopina za infuziju
Erbitux cetuximab
Erbitux cetuksimab
Erbitux is also used to treat ‘squamous cell’ cancers of the head and neck.
Erbitux se također koristi za liječenje karcinoma „skvamoznih stanica” glave i vrata.
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)- expressing, RAS wild-type metastatic colorectal cancer
Erbitux je indiciran za liječenje bolesnika s metastatskim kolorektalnim karcinomom koji iskazuje receptor za epidermalni čimbenik rasta (EGFR) s „divljim tipom“ gena RAS
Erbitux is used in patients whose tumour cells have a protein on their surface called epidermal growth factor receptor (EGFR) and contain ‘wild-type’ (non-mutated) versions of a family of genes called ‘RAS’.
Erbitux se koristi u bolesnika čije tumorske stanice sadrže protein na površini naziva receptor za epidermalni faktor rasta (EGFR) i sadrži verzije „divljeg (nemutiranog) tipa” obitelji gena naziva „RAS”.
Erbitux may be administered via a gravity drip, an infusion pump or a syringe pump.
Erbitux se može primijeniti putem obične infuzije, infuzijske pumpe ili injekcijske pumpe.
Erectile
erektilna
Erectile
Erektilna disfunkcija u
Erectile dysfunction
Erektilna disfunkcija u
Erectile dysfunction
istemskim
Erectile dysfunction Ejaculation disorder Ejaculation delayed
erektilna disfunkcija poremećaj ejakulacije odgođena ejakulacija
Erectile dysfunction in
Erektilna disfunkcija u
Erectile dysfunction in males
Erektilna disfunkcija u muškaraca
Erectile dysfunction in males
erektilna disfunkcija u muškaraca smanjen libido u muškaraca i žena
Erectile dysfunction in males Decreased libido in males and females
erektilna disfunkcija u muškaraca smanjeni libido u muškaraca i žena
Erectile dysfunction in males Decreased libido in males and females
erektilna disfunkcija u muškaraca, smanjen libido u muškaraca i žena
erectile dysfunction medicines (e.g. sildenafil and tadalafil);
lijekovi za liječenje erektilne disfunkcije (npr. sildenafil i tadalafil);
erectile dysfunction medicines, used to treat impotence, such as:
lijekove za erektilnu disfunkciju, primjenjuju se za liječenje impotencije, kao što su:
Erectile dysfunction, as the medicines used to treat erectile dysfunction can cause hypotension and prolonged erection.
Erektilnu disfunkciju, jer lijekovi koji se koriste za liječenje erektilne disfunkcije mogu izazvati hipotenziju i produženu erekciju.
Erectile dysfunction, breast tenderness, nipple pain
erektilna disfunkcija, osjetljivost dojki, bol u bradavicama
erectile dysfunction, ejaculation disorder
erektilni poremećaj, poremećaj ejakulacije
erectile dysfunction, ejaculation disorder, amenorrhoea, menstruation delayed, menstrual disorderd,
erektilna disfunkcija, poremećaj ejakulacije, amenoreja, zakašnjela menstruacija, poremećaj menstruacijed, ginekomastija, galaktoreja, spolna disfunkcija, vaginalni iscjedak
erectile dysfunction, ejaculation disorder, amenorrhoea, menstruation delayed, menstrual disorderd, gynaecomastia,
erektilna disfunkcija, poremećaj ejakulacije, amenoreja, zakašnjela menstruacija, poremećaj menstruacijed, ginekomastija, galaktoreja, spolna disfunkcija, vaginalni iscjedak